Sodium sulfide

Drug Profile

Sodium sulfide

Alternative Names: IK-1001; Metabolic modulation therapeutics - Ikaria Holdings

Latest Information Update: 26 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Ikaria Holdings
  • Class Anti-ischaemics; Sulfides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Reperfusion injury

Most Recent Events

  • 01 May 2015 Ikaria terminates a phase I trial in patients with renal impairment in USA (NCT00879645)
  • 01 Oct 2010 Discontinued - Phase-II for Ischaemic heart disorders in Australia (IV)
  • 01 Oct 2010 Discontinued - Phase-II for Ischaemic heart disorders in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top